Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Cell Immunol. 2019 Apr;338:27-31. doi: 10.1016/j.cellimm.2019.03.002. Epub 2019 Mar 16.
Recently various types of immunotherapies have made immense progress in combating cancer. Adoptive cell therapy, being one of the most favorable forms of immunotherapy, is rapidly moving from bench to bed.
Different types of T-memory cells are being used as promising candidates for adoptive cell therapy: T effector memory (T) cells which are terminally differentiated memory cells and attain effector function soon after re-stimulation; T central memory (T) cells which differentiate into effector T-memory subsets and T-effector cells after antigenic stimulation; and tissue T resident memory (T) cells which fight the tumor insult at the peripheral tissues. Recently, a new subtype of T-memory cells, T stem cell memory (T) have been identified as the most favorable candidate for adoptive cell therapy as they exhibit higher persistence, anti-tumor immunity and self-renewal capacity in the tumor-bearing host.
In this review, we briefly describe the concept and types of T-memory cells as well as their role as potential candidates for anti-cancer immunotherapy.
近年来，各种类型的免疫疗法在抗击癌症方面取得了巨大进展。过继细胞疗法作为最有前途的免疫疗法之一，正在迅速从实验室走向临床。
不同类型的 T 记忆细胞被用作过继细胞疗法的有前途的候选物：T 效应记忆（T）细胞是终末分化的记忆细胞，在重新刺激后很快获得效应功能；T 中央记忆（T）细胞在抗原刺激后分化为效应 T 记忆亚群和 T 效应细胞；组织驻留记忆 T（T）细胞在周围组织中抵抗肿瘤侵袭。最近，一种新的 T 记忆细胞亚群，T 干细胞记忆（T）细胞被确定为过继细胞疗法的最佳候选物，因为它们在荷瘤宿主中表现出更高的持久性、抗肿瘤免疫和自我更新能力。
在这篇综述中，我们简要描述了 T 记忆细胞的概念和类型，以及它们作为抗肿瘤免疫疗法潜在候选物的作用。
